SMMT — Summit Therapeutics Income Statement
0.000.00%
- $5.48bn
- $5.42bn
- 55
- 18
- 84
- 51
Annual income statement for Summit Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 January 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 57.1 | 0.86 | 1.81 | 0.705 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 51.1 | 54.1 | 88 | 72.8 | 610 |
Operating Profit | 6 | -53.2 | -86.2 | -72.1 | -610 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 9.08 | -52.9 | -88.6 | -78.8 | -615 |
Provision for Income Taxes | |||||
Net Income After Taxes | 9.9 | -52.7 | -88.6 | -78.8 | -615 |
Net Income Before Extraordinary Items | |||||
Net Income | 9.9 | -52.7 | -88.6 | -78.8 | -615 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 9.9 | -52.7 | -88.6 | -78.8 | -615 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.774 | -0.75 | -0.961 | -0.364 | -0.992 |
Dividends per Share |